NASDAQ$LENZ
LENZ Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close
Briefing
LENZ Therapeutics reported Q4 2025, revenue of $1.6M, net loss of $35.9M.
For Q4 2025, LENZ Therapeutics reported revenue of $1.6M, a net loss of $35.9M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Revenue $1.6M.
- Net loss $35.9M.
- LENZ Therapeutics MD&A covers liquidity, operations, and outlook.
Headline financials
Revenue & EPS history
LENZ Therapeutics Inc · Revenue · Quarterly
$1.6M
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks; numeric multi-quarter bridges vary by issuer.
Tailwinds
- MD&A highlights liquidity, capital, and core business trends.
- Segment or product commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure near-term margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q4 2025
-2.8%
Avg return
Earnings day
-3.7%
Avg return
5 days after
-5.1%
Avg return
30 days after
20%
2 / 10 earnings
Positive
+5.0%
Q2 2022
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | -7.0% | — | |
| Q1 2026 | -0.8% | -27.1% | -34.5% | |
| Q3 2025 | -23.5% | -17.3% | -4.7% | |
| Q2 2025 | -2.9% | -7.4% | +22.0% | |
| Q3 2023 | -1.7% | -0.4% | -1.3% | |
| Q2 2023 | -4.5% | -4.5% | -17.4% | |
| Q1 2023 | -0.3% | -3.2% | -8.4% | |
| Q3 2022 | +1.9% | +7.1% | +1.9% | |
| Q2 2022 | +5.0% | +9.3% | -9.0% | |
| Q1 2022 | -0.9% | +13.9% | +5.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro